

EHA Research Conference 2025

“Transcriptional control and chromatin alterations in normal and abnormal hematopoiesis”


Abstract Submission Guidelines

The abstract submission guidelines of the EHA Research Conference “Transcriptional control and chromatin alterations in normal and abnormal hematopoiesis” (ReCon 2025) are intended to provide clear instructions before submitting an abstract. **You are kindly requested to carefully read the guidelines stated below.**

EHA and the Scientific Program Committee (SPC) of ReCon 2025 maintain the right to reject any abstract that does not meet the below requirements.

Table of Contents

Abstract Submission Key Dates	2
Deadlines Abstract Submission	2
Terms & Conditions	2
Applicable Law and Jurisdiction	3
Submission Guidelines.....	3
Abstract Topics	3
Submission Specifications	4
Abstract Review, Selection, and Publication.....	4



Abstract Submission Key Dates

June 17, 2024	Abstract submission opens
November 25, 2024 (23:59 CET)	First deadline of abstract submission – Oral & poster presentations
December 6, 2024	First round abstract allocation notification – Oral & poster presentations
December 31, 2024 (23:59 CET)	Deadline of withdrawal for first round abstract submission
January 8, 2025 (23:59 CET)	Second deadline of abstract submission – Poster presentations only
January 17, 2025	Second round abstract allocation notification – Poster presentations only
January 31, 2025 (23:59 CET)	Deadline of withdrawal for second round abstract submission

Deadlines Abstract Submission

There are **two deadlines** for abstract submission of ReCon 2025, which are **November 25, 2024 (23:59 CET)** and **January 8, 2025 (23:59 CET)**. Submissions received after January 8, 2025 (23:59 CET) will not be considered.

- **First abstract submission deadline – Oral and poster presentations**
 - o Submission duration: June 17, 2024 – **November 25, 2024 (23:59 CET)**
 - o Submissions will be considered for oral or poster presentations
 - o Authors will be informed about the allocation by December 6, 2024
- **Second abstract submission deadline – Poster presentations only**
 - o Submission duration: November 26, 2024 – **January 8, 2025 (23:59 CET)**
 - o Submissions will be considered for poster presentations only
 - o Authors will be informed about the allocation by January 17, 2025

Presenters, both oral and poster, must be registered for ReCon 2025 and have the chance to register at the Early Registration Fee (until December 31, 2024). Presenters of an abstract accepted during the second round will receive a discount code to register for the meeting with Early Registration Fee; the discount code will expire on January 31, 2025 (23:59 CET).

Terms & Conditions

1. The SPC encourages the submission of original scientific material unpublished at the time of the abstract submission deadline(s):
 - a. Abstracts submitted to regional or national hematology meetings can be submitted to the EHA Research Conference for inclusion in the program;
 - b. Abstracts submitted to large international meetings which are organized in the same period as the EHA Research Conference (February – April 2025) are allowed to be submitted to the meeting.
 - c. Abstracts submitted to other large international meetings may also be submitted providing a clear indication about significant novel or updated information included in the appropriate abstract submission field.
2. Authors of submitted abstracts shall be the sole and exclusive owner of the abstract and all associated intellectual property rights. By submitting the abstract to EHA, the author grants EHA the right to use and (commercial) reprint the abstract in relation to the EHA Research Conference.

Authors of submitted abstracts understand and agree that EHA will not pay compensation for this license.

3. Authors of submitted abstracts guarantee that the abstract (and all associated intellectual property rights) is free of any third-party rights to the fullest extent permitted by law, including but not limited to, inventor's rights of remuneration and any other ancillary rights.
4. By submitting an abstract, the submitting author confirms that they have approval from all the co-authors to submit and use the data in the abstract.
5. Submitted abstracts are considered embargoed from the time of submission.
6. Please do not submit the same study in multiple abstracts. Abstracts that appear as more than one version of a single study will be rejected.
7. Similarly, abstracts or (close) copies, may not be submitted under more than 1 category.

Applicable Law and Jurisdiction

The above Terms and conditions are governed by the laws of the Netherlands. Any dispute related to these terms and conditions and the use or publication of the abstract shall be exclusively submitted to the District Court in the Hague, the Netherlands.

Submission Guidelines

The submitted abstracts and cases should fully adhere to the guidelines below:

1. Abstracts should be submitted in clear (American) English to allow the reviewers to focus on the scientific content of the abstract. Non-English-speaking authors are encouraged to have their abstract checked for grammar and spelling.
2. The SPC assumes all presenting authors have proficiency in English and, thus are able to present and respond to questions.
3. In clinical studies, please state whether informed consent was obtained from patients.
4. The title and text may not contain trade names. The SPC reserves the right to replace trade names in accepted abstracts.
5. If off label use of drugs was involved, please state this clearly.
6. Withdrawal policy:

If authors wish to withdraw their abstracts from presentation or publication, they are requested to send a letter via e-mail to the EHA Executive Office (eharecon@ehaweb.org). Consequently, the abstract will not be presented nor published.

- Abstract submitted before November 25, 2024 (23:59 CET):
Withdrawal letter (if applicable) should be sent to EHA Executive Office by **December 31, 2024 (23:59 CET)**
- Abstract submitted from November 26, 2024, until January 8, 2025 (23:59 CET):
Withdrawal letter (if applicable) should be sent to EHA Executive Office by **January 31, 2025 (23:59 CET)**

Abstract Topics

Please select the most appropriate topic during the abstract and case submission:

1. Novel RNA biology and epitranscriptomics
2. Transcriptional control in hematopoiesis and hematological malignancies

3. Consequences of mutations in chromatin regulators
4. 3D chromatin architecture and nuclear organization
5. Targeting chromatin regulators in hematology
6. Non-coding genome

Submission Specifications

- Title count: max. 300 characters incl. space.
- Character limit: 3500 characters (incl. spaces & punctuation / excl. headers in the template).
- Please use the following subheadings: Background / Aims / Methods / Results / Summary - Conclusion
- Images have to be submitted as JPEG, tif, or gif files:
 - Due to limited space, only a simple graph/image can be submitted.
 - Images and graphs should reproduce well in black and white.
 - Image file should not exceed 500KB.
- Authors: There is no limit to the number of authors.
- References are obligatory when submitting an abstract

Abstract Review, Selection, and Publication

1. All submitted abstracts will be reviewed by members of the Scientific Program Committee and selected faculty of the EHA Research Conference.
2. Abstracts may be selected for
 - a. Oral presentation
 - b. Poster presentation
 - c. Rejection
3. Only the submitting author will receive a confirmation letter of acceptance for oral presentation, poster presentation, or a notice of rejection, by e-mail by **December 6, 2024**, or **January 17, 2025**, according to the abstract submission time. Note that it is the submitting author's responsibility to inform the presenting author of the abstract allocation outcomes and ensure the presenting author is registered to the meeting to present the abstracts (oral presentation and/or poster presentations).
4. The presenting authors of abstracts selected for an oral presentation will be informed about the date of the session and presentation guidelines will be provided.
5. Oral abstract presenters (excluding poster pitch presenters) will need to register to EHA ReCon 2025 by themselves after receiving the notification in order to present at the meeting. Hotel accommodation will be offered based on their travel itinerary, for a maximum of 3 nights and arranged by EHA.
 - a. Additional nights can be booked by EHA but must be paid by the individual.
6. The presenting authors of abstracts selected for a poster presentation will need to register to EHA ReCon 2025, and will be informed about the date of the poster session and receive guidelines for their presentations.
7. The best abstracts scored as a poster presentation will be selected for an oral 'pitch' presentation in addition to having a poster in the poster area.
8. Authors of abstracts selected for a 'pitch' presentation will be informed about the date of the session and presentation guidelines will be provided.
9. All accepted abstracts will be published in the digital abstract book for meeting attendees. Note that after publication, the abstracts cannot be modified.